Olema (NASDAQ: OLMA) director granted 29,500 stock options at $9.51 strike price
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Olema Pharmaceuticals director Andrew Rappaport received a new stock option grant as part of his compensation. He was awarded options covering 29,500 shares of Olema common stock at an exercise price of $9.51 per share, held directly. The options expire on June 18, 2036.
The grant vests in 12 equal monthly installments starting June 18, 2026, as long as he continues to serve the company. If the options are not fully vested earlier, they vest in full on the date of Olema’s next annual stockholder meeting, again subject to continued service.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
RAPPAPORT ANDREW
Role
null
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (right to buy) | 29,500 | $0.00 | -- |
Holdings After Transaction:
Stock Option (right to buy) — 29,500 shares (Direct, null)
Footnotes (1)
- [object Object]
Key Figures
Option grant size: 29,500 options
Exercise price: $9.51 per share
Shares underlying options: 29,500 shares
+3 more
6 metrics
Option grant size
29,500 options
Stock Option (right to buy) awarded to director
Exercise price
$9.51 per share
Conversion or exercise price of stock option
Shares underlying options
29,500 shares
Underlying Olema common stock
Expiration date
June 18, 2036
Option term end date
Vesting start
June 18, 2026
First of 12 monthly vesting installments
Post-transaction holdings
29,500 options
Total options held following this grant
Key Terms
Stock Option (right to buy), exercise price, vest in a series of 12 successive equal monthly installments, annual meeting of stockholders, +1 more
5 terms
Stock Option (right to buy) financial
"security_title: Stock Option (right to buy)"
exercise price financial
"conversion_or_exercise_price: 9.5100"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vest in a series of 12 successive equal monthly installments financial
"The shares subject to the option vest in a series of 12 successive equal monthly installments"
annual meeting of stockholders regulatory
"Such shares vest in full on the date of the Issuer's next annual meeting of stockholders"
continuous service financial
"subject to the Reporting Person's continuous service through each applicable vesting date"
FAQ
What did Olema Pharmaceuticals (OLMA) director Andrew Rappaport receive in this Form 4 filing?
Andrew Rappaport received a grant of stock options for 29,500 shares of Olema common stock. These options are compensation-related, giving him the right to buy shares at a fixed exercise price over time if he remains in service.
What is the exercise price of Andrew Rappaport’s Olema (OLMA) stock options?
The stock options have an exercise price of $9.51 per share. This means he can buy Olema common stock at $9.51 per share once portions of the option vest, regardless of the market price at that time, while the options remain valid.
How do Andrew Rappaport’s Olema (OLMA) stock options vest over time?
The options vest in 12 equal monthly installments starting on June 18, 2026, contingent on his continuous service. If any portion remains unvested by the issuer’s next annual stockholder meeting, that remainder vests in full on that meeting date, subject to continued service.
When do Andrew Rappaport’s Olema (OLMA) stock options expire?
The stock options expire on June 18, 2036. After this expiration date, any unexercised options become worthless, so exercises must occur before that date once the applicable tranches have vested under the grant terms.
Is Andrew Rappaport buying or selling Olema (OLMA) stock in this Form 4?
This Form 4 reports a grant of stock options, not an open-market buy or sale of shares. It is categorized as a grant or award acquisition, giving him the right to purchase shares in the future if vesting and exercise conditions are met.